The Supreme Court has ruled in favour of Saridon, a heritage brand from the healthcare product portfolio of Piramal Enterprises Ltd. (PEL), exempting its formulation from the list of banned FDCs (fixed dose combinations).
In September 2018, Piramal had obtained a stay order from the Supreme Court on the ban, which allowed it to continue manufacturing, distribution and sale of the fixed dose combination.
Commenting on the Supreme Court ruling, Nandini Piramal, executive director, Piramal Enterprises Ltd., said, “We are pleased with the Supreme Court ruling, as it is an affirmation to our commitment to provide effective and safe healthcare solutions that address unique needs of Indian consumers. We were confident that the law would prevail in our favour. Saridon is a heritage brand trusted by customers for the last 50 years in India. This exemption from the banned list of FDCs validates our intent to serve our customers with the highest levels of integrity. We continue to expand our healthcare product portfolio with an aim to be amongst the top three OTC (over-the-counter) product companies in India by 2020,” she added.
For PEL, Saridon is a ₹100-crore brand, and it is so popular that it is estimated that 31 tablets are sold every second in India.
